Envista Holdings Co. (NYSE:NVST) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lessened its stake in Envista Holdings Co. (NYSE:NVST) by 22.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,242 shares of the company’s stock after selling 4,146 shares during the period. PNC Financial Services Group Inc.’s holdings in Envista were worth $275,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Venturi Wealth Management LLC grew its position in Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after buying an additional 1,638 shares in the last quarter. GAMMA Investing LLC grew its position in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after buying an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new position in Envista in the 4th quarter valued at about $53,000. KBC Group NV grew its position in Envista by 63.9% in the 4th quarter. KBC Group NV now owns 7,903 shares of the company’s stock valued at $152,000 after buying an additional 3,082 shares in the last quarter. Finally, Glenmede Trust Co. NA bought a new position in Envista in the 3rd quarter valued at about $217,000.

Envista Price Performance

NVST stock opened at $16.63 on Friday. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. Envista Holdings Co. has a one year low of $15.15 and a one year high of $23.00. The firm has a market capitalization of $2.86 billion, a PE ratio of -2.56, a P/E/G ratio of 1.27 and a beta of 1.33. The firm has a 50-day moving average of $19.76 and a two-hundred day moving average of $19.59.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Mizuho assumed coverage on shares of Envista in a research report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 target price for the company. JPMorgan Chase & Co. reduced their price objective on shares of Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Jefferies Financial Group raised their price objective on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. New Street Research set a $19.00 price objective on shares of Envista in a research report on Thursday, March 6th. Finally, Morgan Stanley reduced their price objective on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.18.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.